Chemical Strategies To Target Bacterial Virulence

被引:116
作者
Garland, Megan [1 ,2 ]
Loscher, Sebastian [2 ]
Bogyo, Matthew [1 ,2 ,3 ,4 ]
机构
[1] Stanford Univ, Sch Med, Canc Biol Program, 300 Pasteur Dr, Stanford, CA 94305 USA
[2] Stanford Univ, Sch Med, Dept Pathol, 300 Pasteur Dr, Stanford, CA 94305 USA
[3] Stanford Univ, Sch Med, Dept Microbiol & Immunol, 300 Pasteur Dr, Stanford, CA 94305 USA
[4] Stanford Univ, Sch Med, Dept Chem & Syst Biol, 300 Pasteur Dr, Stanford, CA 94305 USA
关键词
ANTHRAX LETHAL FACTOR; BOTULINUM NEUROTOXIN SEROTYPE; SMALL-MOLECULE INHIBITORS; CLOSTRIDIUM-DIFFICILE TOXIN; SHIGA-LIKE TOXIN; HEAT-LABILE ENTEROTOXIN; HEMOLYTIC-UREMIC SYNDROME; ADENYLYL-CYCLASE TOXIN; STRUCTURE-BASED DESIGN; CHOLERA-TOXIN;
D O I
10.1021/acs.chemrev.6b00676
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Antibiotic resistance is a significant emerging health threat. Exacerbating this problem is the overprescription of antibiotics as well as a lack of development of new antibacterial agents. A paradigm shift toward the development of nonantibiotic agents that target the virulence factors of bacterial pathogens is one way to begin to address the issue of resistance. Of particular interest are compounds targeting bacterial AB toxins that have the potential to protect against toxin-induced pathology without harming healthy commensal microbial flora. Development of successful antitoxin agents would likely decrease the use of antibiotics, thereby reducing selective pressure that leads to antibiotic resistance mutations. In addition, antitoxin agents are not only promising for therapeutic applications, but also can be used as tools for the continued study of bacterial pathogenesis. In this review, we discuss the growing number of examples of chemical entities designed to target exotoxin virulence factors from important human bacterial pathogens.
引用
收藏
页码:4422 / 4461
页数:40
相关论文
共 281 条
[41]   Fungal bis-Naphthopyrones as Inhibitors of Botulinum Neurotoxin Serotype A [J].
Cardellina, John H., II ;
Roxas-Duncan, Virginia I. ;
Montgomery, Vicki ;
Eccard, Vanessa ;
Campbell, Yvette ;
Hu, Xin ;
Khavrutskii, Ilja ;
Tawa, Gregory J. ;
Wallqvist, Anders ;
Gloer, James B. ;
Phatak, Nisarga L. ;
Hoeller, Ulrich ;
Soman, Ashish G. ;
Joshi, Biren K. ;
Hein, Sara M. ;
Wicklow, Donald T. ;
Smith, Leonard A. .
ACS MEDICINAL CHEMISTRY LETTERS, 2012, 3 (05) :387-391
[42]   A receptor decoy inhibits the enterotoxic effects of Clostridium difficile toxin a in rat ileum [J].
Castagliuolo, I ;
LaMont, JT ;
Qiu, BS ;
Nikulasson, ST ;
Pothoulakis, C .
GASTROENTEROLOGY, 1996, 111 (02) :433-438
[43]   Detection of mcr-1 among Escherichia coli Clinical Isolates Collected Worldwide as Part of the SENTRY Antimicrobial Surveillance Program in 2014 and 2015 [J].
Castanheira, Mariana ;
Griffin, Michelle A. ;
Deshpande, Lalitagauri M. ;
Mendes, Rodrigo E. ;
Jones, Ronald N. ;
Flamm, Robert K. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2016, 60 (09) :5623-5624
[44]   The biology and future prospects of antivirulence therapies [J].
Cegelski, Lynette ;
Marshall, Garland R. ;
Eldridge, Gary R. ;
Hultgren, Scott J. .
NATURE REVIEWS MICROBIOLOGY, 2008, 6 (01) :17-27
[45]  
Centers for Disease Control and Prevention, 2016, DIPHTH
[46]  
Centers for Disease Control and Prevention, 2016, SHIG SHIG
[47]  
Centers for Disease Control and Prevention, 2007, BIOT OV
[48]   ANION-EXCHANGE RESINS IN ANTIBIOTIC-ASSOCIATED COLITIS [J].
CHANG, TW ;
ONDERDONK, AB ;
BARTLETT, JG .
LANCET, 1978, 2 (8083) :258-258
[49]   Capsaicin, a potential inhibitor of cholera toxin production in Vibrio cholerae [J].
Chatterjee, Shruti ;
Asakura, Masahiro ;
Chowdhury, Nityananda ;
Neogi, Sucharit Basu ;
Sugimoto, Norihiko ;
Haldar, Soumya ;
Awasthi, Sharda Prasad ;
Hinenoya, Atsushi ;
Aoki, Shunji ;
Yamasaki, Shinji .
FEMS MICROBIOLOGY LETTERS, 2010, 306 (01) :54-60
[50]   Toxins A and B from Clostridium difficile differ with respect to enzymatic potencies, cellular substrate specificities, and surface binding to cultured cells [J].
ChavesOlarte, E ;
Weidmann, M ;
vonEichelStreiber, C ;
Thelestam, M .
JOURNAL OF CLINICAL INVESTIGATION, 1997, 100 (07) :1734-1741